Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex Ipsogen JAK2 DX

Sysmex has launched the ipsogen JAK2 DX reagent after the product received health insurance coverage in Japan on Jan. 1. The Kobe, Japan-based firm said that it received marketing approval for the gene testing kit that measures the JAK2V617F mutation quantitatively in December 2018. The test is used to diagnose certain hematopoietic tumors, specifically polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Sysmex inked a distribution deal with Ipsogen (now part of Qiagen) in 2011 covering Japan that allows Sysmex to distribute some Ipsogen blood cancer products in that country.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.